CSCI vs. ATRA, PEPG, AVTX, ARTV, IPSC, MRSN, NRXP, VRCA, PMVP, and AKTX
Should you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Atara Biotherapeutics (ATRA), PepGen (PEPG), Avalo Therapeutics (AVTX), Artiva Biotherapeutics (ARTV), Century Therapeutics (IPSC), Mersana Therapeutics (MRSN), NRx Pharmaceuticals (NRXP), Verrica Pharmaceuticals (VRCA), PMV Pharmaceuticals (PMVP), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry.
COSCIENS Biopharma vs.
COSCIENS Biopharma (NASDAQ:CSCI) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
Atara Biotherapeutics has a net margin of -132.58% compared to COSCIENS Biopharma's net margin of -428.43%. Atara Biotherapeutics' return on equity of 0.00% beat COSCIENS Biopharma's return on equity.
In the previous week, Atara Biotherapeutics had 2 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 3 mentions for Atara Biotherapeutics and 1 mentions for COSCIENS Biopharma. COSCIENS Biopharma's average media sentiment score of 1.17 beat Atara Biotherapeutics' score of 0.67 indicating that COSCIENS Biopharma is being referred to more favorably in the media.
Atara Biotherapeutics has a consensus target price of $17.75, indicating a potential upside of 92.31%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atara Biotherapeutics is more favorable than COSCIENS Biopharma.
Atara Biotherapeutics received 437 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users.
0.7% of COSCIENS Biopharma shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 0.1% of COSCIENS Biopharma shares are owned by company insiders. Comparatively, 4.0% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
COSCIENS Biopharma has higher earnings, but lower revenue than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks.
COSCIENS Biopharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.
Summary
Atara Biotherapeutics beats COSCIENS Biopharma on 12 of the 18 factors compared between the two stocks.
Get COSCIENS Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
COSCIENS Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:CSCI) was last updated on 6/7/2025 by MarketBeat.com Staff